Click here if you are having trouble viewing this message.

April newsletter

Spotlight on: Manufacturing

In this manufacturing focussed newsletter, we are pleased to provide updates on the progress being made at the CGT Catapult manufacturing centre in Stevenage.

We have recently announced the fifth company to be collaborating at the centre to develop their manufacturing processes. TCR² Therapeutics are the first US company to choose Stevenage as its global base for manufacture of next-generation novel T-cell receptor therapies.

Autolus has also become the first of the centre collaborators to be granted a manufacturing licence variation, allowing them to manufacture products for clinical trial at the centre.

Construction is continuing to progress to expand the centre, with the construction of six additional modules in the space on the second floor of the building. Construction is supported by £3.36m funding from the European Regional Development Fund (ERDF) and a £12m Industrial Strategy Challenge Fund (ISCF) award.

For a more detailed update on the CGT Catapult manufacturing centre, please see this document.

Download the centre update.

Expansion of the CGT Catapult manufacturing centre continues

Share this email on social media

News

Celebrating one year of operation at the CGT Catapult manufacturing centre
Supporting the UK industry, five companies are developing their GMP manufacturing processes at the centre and they can now leverage the centre's MHRA licences to manufacture for clinical trial and commercial supply.
Find out more

Regulatory news
Regulatory news from around the world including the European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA) and Food and Drug Administration (FDA).
Regulatory news

Bringing SMEs together with investors to secure funding for the UK industry
Along with Fujifilm Diosynth Biotechnologies, Eversheds Sutherland, Mathys & Squire and Stifel we bought the investor community together with ATMP companies in order to support companies in attracting investment.
Find out more

iMATCH ATTC given boost for expanding use of cell and gene therapies in the UK
The SAMPLE programme to help build capacity for the NHS to expand the use of cell and gene therapies has been given the green light by Innovate UK.
Read the press release

Meet us at these upcoming events

Phacilitae Automation SIG
Lake Maggiore, Italy
08 - 09 May 2019

Director of Industrialisation - New and Enabling Technologies, Dr Damian Marshall, will be chairing the session on Cell production monitoring and analytics - a look towards artificial intelligence

World Advanced Therapies and Regenerative Medicine Congress 2019
London, UK
15 - 17 May 2019

Chief Clinical Officer, Dr Jacqueline Barry, will be taking part in a clinical trials focussed workshop discussing What needs to be done to get these experimental treatments to patients in the clinic?

Dr Barry will also be chairing the panel: Advanced Therapies Treatment Network: facilitating adoption, proof of adoption and how we get there, challenges and adoption

We are also co-sponsoring the 2019 Networking Reception and look forward to seeing many of you there.

+44 (0) 203 728 9500
12th Floor Tower Wing, Guy’s Hospital, Great Maze Pond, London SE1 9RT

The Cell and Gene Therapy Catapult takes your data very seriously, you can read how we may use it in our privacy policy. If you no longer want to hear from us unsubscribe here.